THE HEMATOLOGY/ONCOLOGY PHARMACY ASSOCIATION IS A NONPROFIT EDUCATION-BASED ORGANIZATION.

Our mission is to support pharmacy practitioners and promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer.
Bringing It All Together

We are pleased to provide HOPA’s 2018 Annual Report: “Bringing It All Together.”

The hallmarks of 2018 for HOPA were growth and inclusion. We began the year by further defining who our members are and where they practice. Through the work of a dedicated task force led by Lisa Holle, we built on the work done in 2013 to outline new practice parameters in “Further Defining the Scope of Hematology/Oncology Pharmacy Practice.” It is clear that the HOPA membership is expanding beyond the walls of the academic medical center, which allows us to move closer to achieving our mission of having a hematology/oncology pharmacist on the care team of all oncology and hematology patients. Pharmacists—whether they are embedded within multidisciplinary cancer care teams, administering care in infusion centers and clinical research units, developing therapy innovations through the industry, dispensing oral chemotherapy in community and specialty pharmacies, or teaching the best and brightest of our future pharmacists—ultimately help deliver effective patient care with improved outcomes in a variety of settings.

In 2018 our annual conference, held in Denver, attracted our largest attendance to date! The conference included 8 hours of Board Certified Oncology Pharmacist education, a Practice Management Boot Camp, and an engaging session of roundtable discussions on crucial topics in oncology pharmacy leadership. At that conference we also previewed the HOPA Ahead brand to be used for future conferences, which will allow us to build on our most important educational product and better identify the unique and highly sought after professional development opportunities that HOPA offers. The Leadership Development Committee also began work that culminated with the launch of a pilot program for mentors and mentees, matching past and present HOPA leaders with future leaders and ensuring that HOPA’s leadership pipeline will remain full. Another action taken to support the growth of future leaders in HOPA was to make membership in HOPA free to pharmacy students. This decision will allow more pharmacy students to see the benefits of pursuing a career in oncology pharmacy and the value of being a HOPA member.

We started the 2018 year with the idea that it is through healthcare quality that HOPA members can best demonstrate the value of their contributions. A task force under the leadership of Emily Mackler and Amy Seung helped us further define those opportunities, and that task force became the Quality Oversight Committee. The future of health care will demand the delivery of high-quality, value-based care, and it will be through the leadership of HOPA members that the significance of the hematology/oncology pharmacist in delivering that care will be established.

HOPA has become the true home for oncology/hematology pharmacy: we have expanded and diversified our membership, increased meeting attendance, provided more and varied educational opportunities, and enhanced the number and value of our collaborations. We look forward to working with all of you to secure our shared future in health care.

Ryan Bookout, PharmD BCOP
2018–2019 HOPA President

Michael M. Bourisaw
Executive Director
In 2018, HOPA reached more than 3,000 members. Our membership continues to expand across the globe, with members making contributions to the field and growing professionally in new specialties and evolving practice settings.
### Membership

<table>
<thead>
<tr>
<th>Year</th>
<th>Full Members</th>
<th>Residents/Fellows/Trainees</th>
<th>Associate Members</th>
<th>Students</th>
<th>Pharmacy Technicians</th>
<th>Lifetime Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>631</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>832</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>979</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>1,240</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>1,355</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>1,632</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>1,756</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>1,881</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>1,995</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>2,152</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>2,357</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>2,681</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>2,836</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>3,025</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Specialties Represented*

- **Oncology**: 73%
- **Hematology**: 43%
- **Geriatrics/Adults**: 38%
- **Clinical Practice**: 29%
- **Supportive Care**: 20%
- **Bone Marrow Transplantation**: 18%
- **Administration**: 17%
- **Research**: 15%
- **Education**: 12%
- **Palliative Care**: 8%
- **Pediatrics**: 7%
- **Infectious Disease**: 2%
- **Radiology**: .4%
- **Advocacy**: .4%
- **Nuclear Medicine**: .3%
- **Other**: 9%

*The percentages total more than 100% because members may select more than one specialty.

### Practice Sites

- **Academic Center or Institution**: 28%
- **Community Cancer Center, Hospital, or Pharmacy**: 19%
- **Outpatient Infusion Center**: 13%
- **Inpatient Hospital**: 9%
- **Industry**: 7%
- **Ambulatory Care Center**: 6%
- **Government, Not-for-Profit Organization, or Managed Care**: 5%
- **For-Profit, Private, or Medical Office**: 2%
- **Specialty Pharmacy or Distribution**: 1%
- **Other**: 10%
2018 PROGRAM FINANCIALS*

TOTAL OPERATING REVENUE

$4,955,069

42.8%
Sponsorship
$2,121,167

21.4%
Registration Fees
$557,521

11.2%
Membership Dues
$368,861

8.3%
Commissions/Royalties
$135,338

7.4%
Sales
$237,835

4.8%
Other
$61,466

1.2%
Educational Grants
$410,000

TOTAL OPERATING EXPENSES

$4,669,991

36.8%
Conference, Symposia, & Courses
$1,720,985

15.8%
General & Administrative
$565,223

12%
Membership
$281,130

10.2%
BCOP & Other Education
$475,811

6%
Industry Relations Council
$228,157

5.7%
Health Policy & Summits
$268,440

4.9%
Newsletter/Professional Resources & Standards
$169,523

4.8%
Research Committee
$224,054

3.6%
Board/External Involvement
$736,668

*The numbers are audited as of July 31, 2019.
Three years ago, HOPA set forth a 5-year strategic plan, and in 2018, we are proud to announce the near completion of the plan in these four goal areas:

Professional Development

Professional Resources and Tools

Research

Advocacy
PROFESSIONAL DEVELOPMENT

Developing hematology/oncology pharmacists as valuable members of the cancer care team, excelling within their institutions and profession
2018 Annual Conference
HOPA’s 14th Annual Conference had its largest attendance to date, with more than 1,400 HOPA members and industry professionals hosted at the Colorado Convention Center in Denver. The conference included educational sessions on significant papers in oncology, new drug therapies, patient care, and advanced pharmacy practices and offered 8 Board Certified Oncology Pharmacist (BCOP) credits. New at the 2018 Annual Conference was the addition of electronic posters (e-posters), allowing greater opportunities for engagement between research presenters and attendees.

BCOP Recertification
In April the BCOP Oversight Committee convened in Chicago, IL, to discuss the recent improvements and expansions made to the BCOP program over the past year. This meeting led to overall course improvements, such as the addition of case studies to the BCOP Self-Study program to foster a closer application of course content to the real-life experiences of patients. We continue to listen to feedback from those taking our BCOP courses and have made several adjustments to internal processes to produce better, more timely education for our members. In 2018 we had 736 members and nonmembers take advantage of HOPA’s BCOP courses and bundled products.

Work with Allied Organizations
Throughout 2018, HOPA engaged with the National Community Oncology Dispensing Association, Oncology Nursing Society, and Association of Community Cancer Centers to deliver oral chemotherapy education for both patients and caregivers. We began discussions with the Pharmacy Quality Alliance about how HOPA could be involved in developing quality metrics in oncology pharmacy. At our annual conference we hosted the Society of Pain and Palliative Care Pharmacists, who developed and delivered a preconference session on the role of pharmacists in palliative care. HOPA also entered into an agreement with the American College of Clinical Pharmacy (ACCP) to support HOPA members involved in research through ACCP’s Mentored Research Investigator Training (MeRIT) and Focused Investigator Training (FIT) mentorship programs. Finally, HOPA was represented by Emily Mackler, PharmD BCOP, at the American Society of Clinical Oncology’s Quality Training Program learning session, with the goal of expanding the relationship and exploring future opportunities for HOPA members.

Practice Management
In September HOPA delivered its 6th Annual Practice Management Program in Chicago, IL. More than 200 pharmacy leaders gathered to learn, network, and listen to comprehensive presentations on electronic health records, finance and reimbursement, and opportunities in oncology quality as well as an update on the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).

Women in Leadership
Following the 2017 Women Leadership in Oncology Pharmacy Summit, held in conjunction with the Oncology Pharmacy Practice Management Program, HOPA’s Women in Leadership Task Force began to develop a white paper summarizing the discussion from the summit and outlining important next steps in addressing the needs and status of women leaders in our fields of practice. In 2018 HOPA’s Leadership Development Subcommittee continued the work initiated by the Women in Leadership Task Force and finalized the white paper.

Oncology Pharmacy Collaboration
HOPA expanded its relationship with Walgreens Specialty Pharmacy during 2018. A visit to the Walgreens site at Northwestern Medical Center in Chicago enabled HOPA board members to learn more about the integration of specialty pharmacy into an academic medical center. Walgreens also increased its presence at the HOPA AHEAD conference: more than 15 staff members from various specialty pharmacy locations attended. In addition, HOPA member Jennifer Powers of Walgreens presented data derived from our joint education program, showing the value of live training to pharmacists who are seeking to give better support to patients during engagement with them.

Additional Learning Opportunities
In 2018 HOPA delivered 10 journal club meetings facilitated by our postgraduate year-2 oncology residents. These webinars covered topics and research in patient management and therapeutics. HOPA also hosted several webinars during the year, covering the topics of oncology reimbursement, the roles and responsibilities of the pharmacy technician in ambulatory oncology pharmacy, and opioid prescribing for cancer patients.
PROFESSIONAL RESOURCES AND TOOLS

Providing the professional resources and tools needed to support hematology/oncology pharmacists across the cancer care continuum
Guidelines for Oncology Pharmacy Technicians
In collaboration with the American Society of Health-System Pharmacists, HOPA published the “ASHP-HOPA Guidelines on the Roles and Responsibilities of the Pharmacy Technician in Ambulatory Oncology Care.” These guidelines address the rapid evolution of ambulatory oncology practice in recent decades.

In July 2018, the HOPA Standards Committee organized a work group of oncology pharmacy specialists to enhance our pharmacy practice standard for the management of oral oncolytic therapy. The document describes the pharmacist’s role on the cancer care team, provides examples of practice tools and resources, summarizes current data related to outcomes, and discusses opportunities to enhance the care of patients with cancer who receive oral oncolytic therapy.
RESEARCH

Establishing HOPA as a leader in research on hematology/oncology pharmacy intervention and impact

In 2018 HOPA increased its grant funding from $100,000 to $150,000 and collaborated with AstraZeneca to offer an additional sponsored grant of $50,000, bringing the total amount of available grant funds to $200,000. This funding allowed for the funding of four research projects in 2018.
The purpose of Dr. Draper and Dr. Harvey’s study is to determine whether extending each oxaliplatin infusion from 2 hours to 6 hours in patients receiving FOLFOX6, and thereby reducing Cmax values, will lead to a commensurate decline in the incidence and severity of chronic dose-limiting sensory neuropathy. Using an altered dosing strategy to reduce peak concentrations—and therefore prevent or reduce neurotoxicity or prolong the time before neurotoxicity is reached—will improve treatment adherence, treatment tolerability, and post-treatment toxicity.

The objective of Dr. Marini’s study is to improve the selection of precision medicine therapies for pediatric brain tumor patients by optimizing the Central Nervous System Targeted Agent Prediction (CNS TAP) algorithm. If the project is successful, the results will not only lead to improved outcomes for brain tumor patients but also help those advocating for the continued involvement of hematology/oncology clinical pharmacists at the forefront of precision medicine initiatives in oncology practice.

The central objective of Dr. Hughes’s study (funded by the AstraZeneca-sponsored grant) is to evaluate whether CYP3A5 polymorphisms can predict the toxicity profile of myalgias or arthralgias and atrial fibrillation in patients treated with ibrutinib. The results of the study will provide data useful for further understanding of the impact of pharmacogenomic variability on the incidence of toxicity. This contribution will help determine the feasibility of genomic testing for ibrutinib used in toxicity management and propose future research to minimize the toxicity of agents and maximize the patient’s ability to tolerate the drug and have more time on ibrutinib prior to starting a new line of therapy.

Dr. Crona’s study aims to develop a precision dosing tool for oral chemotherapeutics that will be used exclusively by providers (e.g., clinician pharmacists) but will be beneficial to providers and patients alike. If successful, the developed tool has the opportunity to contest the “one-size-fits-all” dosing model and pave a path for new research in precision dosing for oral chemotherapeutics.
ADVOCACY

Speaking up for the value of hematology/oncology pharmacy and influencing issues related to patients’ cancer care
HOPA on the Hill
HOPA for the first time opened up opportunities for members at large to participate in its Hill Day activities. HOPA took 30 members to Capitol Hill as part of its continued efforts to enlighten the legislature on the value of hematology/oncology pharmacists.

Collaborations
HOPA joined the Pharmacy Health Information Technology Collaborative as a voting member to ensure that the perspective of hematology/oncology pharmacists is considered as this larger group seeks to integrate the pharmacist’s perspective into the national health information technology interoperable framework.

Letters of Support and Comment Letters
Throughout the year HOPA was alert to the changing landscape of health care and provided HOPA’s perspective where appropriate. We provided commentary on President Trump’s American Patients First blueprint when the request for information came to us in the summer. HOPA signed letters from the Cancer Leadership Council (CLC) regarding the U.S. Food and Drug Administration’s Biosimilars Action Plan as well as a letter from CLC opposing legislation that would have allowed Medicare Advantage plans to implement step therapy for Part B drugs. We took a stance against the pharmacists’ gag rules that prevented pharmacists from telling customers when they could save money by paying the pharmacy’s lower cash price instead of the price negotiated by their insurance plan and were pleased to see the passing of legislation banning such clauses. HOPA also signed on to a letter of the American Society of Clinical Oncology supporting HR 6836, which ensures that Medicaid beneficiaries enrolled in clinical trials receive coverage of routine items and services that they may require in connection with their treatment.
In 2018, HOPA continued to collaborate and partner with some outstanding organizations and participate in coalitions, councils, events, and other professional campaigns:

Academy of Managed Care Pharmacy
Accreditation Council for Pharmacy Education
Advanced Practitioner Society for Hematology and Oncology
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Institute of the History of Pharmacy
American Pharmacists Association
American Society for Blood and Marrow Transplantation
American Society of Clinical Oncology
American Society of Consultant Pharmacists
American Society of Hematology
American Society of Pediatric Hematology/Oncology
Association of Community Cancer Centers
Association of Pediatric Hematology/Oncology Nurses
Biologics and Biosimilars Collective Intelligence Consortium
Board of Pharmaceutical Specialties
Cancer Center Antimicrobial Stewardship Group
Cancer Support Community
Commission on Cancer
International Society of Oncology Pharmacy Practitioners
Joint Commission of Pharmacy Practitioners
Leukemia and Lymphoma Society
National Alliance of State Pharmacy Associations
National Association of Boards of Pharmacy
National Association of Specialty Pharmacy
National Cancer Institute
National Community Oncology Dispensing Association
National Community Pharmacists Association
National Comprehensive Cancer Network
National Institute for Occupational Safety and Health
National Quality Forum
Oncology Nursing Society
Pancreatic Cancer Action Network
Pediatric Pharmacy Advocacy Group
Pharmacy Health Information Technology Collaborative
Pharmacy Quality Alliance
Pharmacy Workforce Center
Society for Immunotherapy of Cancer
Society of Pain and Palliative Care Pharmacists
INDUSTRY RELATIONS COUNCIL (IRC)

HOPA’s IRC program brings benefits to both HOPA and the participants, fostering relationships and dialogue among key representatives of the hematology/oncology pharmacy industry with the goal of promoting optimal, cost-effective care for patients affected by cancer. In 2018, the IRC had 25 council participants at the Premier, Executive, and Associate levels.

**PREMIER**
- AstraZeneca
- Bristol-Myers Squibb
- Celgene
- Exelixis
- Genentech
- Lilly Oncology
- Pfizer Oncology

**EXECUTIVE**
- Amgen
- Boehringer Ingelheim
- Helsinn Therapeutics
- Jazz Pharmaceuticals
- Merck
- Pharmacyclics

**ASSOCIATE**
- Apobiologix
- Array BioPharma
- Cumberland
- Eisai
- Novartis Oncology
- Walgreens
2018 MEMBERSHIP AWARDS

HOPA members continue to do amazing work in the field of hematology/oncology pharmacy, and HOPA recognizes the significant achievements of those members with its annual awards and recognition program.

Award of Excellence

R. Donald Harvey, PharmD BCOP FCCP FHOPA
Emory University School of Medicine

Donald Harvey is an associate professor in the Department of Hematology and Medical Oncology in the School of Medicine and director of the Phase I Clinical Trials Section at the Winship Cancer Institute of Emory University. He obtained his BS and PharmD degrees at the University of North Carolina (UNC). His research in anticancer early drug development focuses on the application of clinical pharmacology principles to improve patient care. He has been co-investigator or principal investigator on more than 50 phase 1 and clinical pharmacology trials since beginning his work at Emory in 2009 and is the author of more than 60 peer-reviewed publications. Organ dysfunction, drug interaction, food effects, and pharmacokinetically driven trials are areas of interest for Dr. Harvey and his group. He is also active in a number of clinical pharmacology and hematology/oncology professional organizations, including the American Society of Clinical Oncology, the American Society for Clinical Pharmacology and Therapeutics, and the American Society of Hematology. He is a past president of HOPA and currently chairs HOPA’s Research Committee.

New Practitioner Award

Alexandra Shillingburg, PharmD BCOP
Levine Cancer Institute, Carolinas HealthCare System

Alexandra Shillingburg is bone marrow transplantation pharmacist clinical coordinator at the Levine Cancer Institute in the Carolinas HealthCare System in Charlotte, NC. Earlier she served as director of the Stem Cell Collection and Apheresis Program and the Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program at the West Virginia University Cancer Institute. She has contributed articles to many journals on topics in hematology, oncology, clinical trials, pathology, and pediatrics and has presented at many state, regional, and national meetings. She has been a noted innovator and leader in developing hematopoietic cell transplantation pharmacy programs.

Technician Award

Desiree Rolniak, CPhT
MD Anderson Cancer Center

Desiree Rolniak, CPhT, is a specialty pharmacy technician in investigational pharmacy services at MD Anderson Cancer Center in Houston, TX. Earlier she served as a pharmacy technician for the U.S. Air Force Academy. Her civil service experience in the U.S. Air Force, project management expertise, and exceptional analytical skills have contributed to her notable success as a specialty technician.
HOPA FELLOWS

In 2018, HOPA was pleased to announce the members of its third class of Fellows of the Hematology/Oncology Pharmacy Association (FHOPA). This designation recognizes individuals who have made sustained contributions to HOPA and have demonstrated exceptional performance in oncology pharmacy.

Robert J. Ignoffo, PharmD FASHP FCSHP FHOPA

Michelle L. Rockey, PharmD BCOP FHOPA

Sachin Shah, PharmD BCOP FCCP FHOPA
2018–2019 HOPA BOARD OF DIRECTORS, COMMITTEES, SUBCOMMITTEES, TASK FORCES, AND WORK GROUPS

HOPA BOARD OF DIRECTORS

President
Ryan Bookout, PharmD BCOP BCPS

Immediate Past President
Susannah Koontz, PharmD BCOP FHOPA

President Elect
Susanne Liewer, PharmD BCOP FHOPA

Treasurer
Jolynn Sessions, PharmD BCOP

Secretary
Sally Barbour, PharmD BCOP

At-Large Directors
Larry Buie, PharmD BCOP FASHP
Heidi Finnes, PharmD BCOP (July–December), not pictured
Edward Li, PharmD MPH BCOP (January–June)
LeAnn Norris, PharmD BCOP BCPS FCCP
Jeremy Whalen, PharmD BCOP
Advocacy Council
Kate Jeffers, External/Professional Affairs Committee Chair
Tim Tyler, Public Policy Committee Chair
Kellie Weddle, Patient Outreach Committee Chair
Ryan Bookout, Board Liaison
Susannah Koontz, Board Liaison
Susanne Liewer, Board Liaison

Annual Conference Committee
Katharine Kinsman, Chair
Hillary Prescott, Vice Chair
Larry Buie, Board Liaison
Melissa Bourque
Kelley Carlstrom
Jenna Carmichael
Sean Cosgriff
Morgan Gwynn
Julie Kennerly-Shah
Jacob Kettle
Cameron Ninos
Michael Oholendt
Danielle Roman
Leslie Ward
Nicole Watts
Kristin Wheatley

Annual Conference Abstract Review Subcommittee
Kayeleigh Marx, Chair
John Bossaer, Vice Chair
Benjamin Andrick
Jason Barreto
Margaret Charpentier
Bryna Delman
Justina Frimpeng
Arpita Gandhi
Steven Gilmore
Sara Kim
Katherine Morgan
Samantha Reiss
Danielle Schlafer
Marisela Tan
Colleen Westendorf-Overley
Shardae Young
Mark Zangardi

Annual Conference Session Proposal Subcommittee
Devon Greer, Chair
Brittney Hale, Vice Chair
Brooke Adams
Young Bae
Bonnie Boster
Marc Earl
Dwight Eplin
Kelly Gaertner
Stefanie Houseknecht
Jennifer LaFollette
Melissa Mackey

Anne McDonnell
Jennifer Pauley
Amber Proctor
Jeremy Sen
Teresa Thakrar
Sarah Ann Tucker
Catherine Wallace

BCOP Oversight Committee
Amy Pick, Chair
Ila Saunders, Vice Chair
Larry Buie, Board Liaison
LeAnn Norris, Board Liaison
Jeremy Whalen, Board Liaison
Heidi Finnes, Mentor
M. Brooke Bernhardt
Rowena Schwartz
Melissa Stricherz

BCOP Conference Programming Subcommittee
Jason Bergsbaken, Chair
Jeanne McCarthy-Kaiser, Vice Chair
Larry Buie, Board Liaison
Mary Chi
Eric Chow
Richard Fong
Katie Gatwood
Angela German
Megan Hinkley
Elizabeth Koselke
Diana Kostoff
Jose Murillo
Maribel Pereiras
Amy Pick
Ila Saunders
Scott Wirth

BCOP Field Testing Subcommittee
Nikki Ogle, Chair
Bradley Beck, Vice Chair
Cory Bivona
Nicholas Link
Amy Pick
Ila Saunders
Starla Swaim

BCOP Item Writing Subcommittee
Christy Harris, Chair
Amy Pick, Vice Chair
LeAnn Norris, Board Liaison
Lisa grate
Jennifer Kwon
Chung-Shien Lee
Rebecca Parrow

BCOP Self-Study and Webinar Courses Subcommittee
Colleen Timlin, Chair
Kelly Hawks, Vice Chair
LeAnn Norris, Board Liaison
Lin Aleandro
Matthew Arango

Chad Barnett
Matthew Eckley
Joshua Elder
Laura Geswein
Kirolos Hanna
Rebekah Hartwell
Maho Hibino
Syeda Saba Kareem
Catherine Lee
Suwicha Limvorsak
Robert Mancini
Sherry Mathew
Jocelyn Mohs
Carmen Nobre
Alison Palumbo
Amy Pick
Ila Saunders
Sarah Hoppes Schmidt
Jennifer Swank
Jennifer Zadlo
Chrystia Zobniw

BCOP Updates Course Subcommittee
Meredith Moorman, Chair
Allison Baxley, Vice Chair
LeAnn Norris, Board Liaison
Salma Affifi
Laura Bobolts
Nicole Kaiser
Shawna Kraft
Samantha Luk
Jennifer Piccolo
Amy Pick
Ila Saunders
Anand Shah
Jamie Shapiro
Rebecca Young
Milena Zhang

Education Council
Lindsey Amerine, Practice Management Program Committee Chair
Sara Butler, Education Development Committee Chair
Katharine Kinsman, Annual Conference Committee Chair

Caroline Oxencis, Needs Assessment Committee Chair
Amy Pick, BCOP Oversight Committee Chair
Larry Buie, Board Liaison
LeAnn Norris, Board Liaison
Jeremy Whalen, Board Liaison

Mary Mably
Megan Brafford May
Sarah Wheeler

External/Professional Affairs Committee
Kate Jeffers, Chair
Jaime Anderson, Vice Chair
Sonnya Chandrasekhar
Sarah Kraus Cimino
Renee Curtis-Freitag
Samuel Jacobson
Puja Patel

Finance Committee
Jolynn Sessions, Chair
Ryan Bookout, Vice Chair
Susanne Liewer, Board Liaison
Val Adams
James Hoffman

Grant Reviewers Committee
Meghana Trivedi, Chair
Pamala Pawloski, Vice Chair
Kristine Crews
Cyrine Haidar
Hansen Ho
Mark Kirstein
Kimberly Lau
Claire Mach
Jeanne McCune
Shanada Monestime
Alan Myers
Jacky Olin
Janelle Perkins
Brian Primeaux

Industry Relations Council Committee
Andrea Ledford, Chair
Susan Liewer, Board Liaison
Jim Koeller
Adam Peele
Casey Williams

Leadership Development Subcommittee
Phil Johnson, Chair
Rebecca Fahrenbruch, Vice Chair
Ryan Bookout, Board Liaison
Matthew Chui
Sandra Cuellar
Raj Duggal
Dave Henry
Cindy O’Bryant
John Orr-Skirvin
Alexandra Shillingburg
Steve Sticker

Membership Committee
Brandon Shank, Chair
Elyse Panici, Vice Chair
Michelle Amsler
Ekim Ekinci
Michael Fusco
Alexis Kuhn
Jessica Lawton
Jessica Lu
Kathryn Maples
Ronni Miller
Mallika Patel
Alexandra Warner
Michael Williams

Needs Assessment Committee
Carolyn Oxencis, Chair
Debra Chibroski, Vice Chair
Eve Segal, Mentor
Alison Duffy
Joseph Kalis
Darren Luon
Kristen McCullough
Lauren McGinty
Kate Reichert
Amber Rexwinkle
Eve Segal
Tina Tweedley

Nominations Subcommittee
Daisy Yang, Chair
Amber Lawson, Vice Chair
Susannah Koontz, Board Liaison
Nelly Adel
Christopher Fausel
Stephanie Willenbring
Dan Zlott

Patient Outreach Committee
Kellie Weddle, Chair
Jill Rhodes, Vice Chair
James Connelly
Andrea Dickens
Mandy Gatesman
Jordan Hill
Julianne Orr
Mark Peters
Jennifer Powers
Andrew Throne
Eris Tollkuci
Ari Whitman

Practice Management Program Committee
Lindsey Amerine, Chair
Jeff Lombardo, Vice Chair
Jeremy Whalen, Board Liaison
Sapna Amin
Corbin Bennett
Elizabeth Hansen
Heather Jones
Jeffrey Reichard
Michelle Rockey
Philip Schwieterman
Brandy Snyder
John Valgus

Professional Practice Council
Ashley Glode, Publications
  Committee Chair
Caren Hughes, Tools and Resources
  Committee Chair
LeAnne Kennedy, Recognition
  Committee Chair
Brandon Shank, Membership
  Committee Chair
Lindsay Stansfield, Standards
  Committee Chair
Heidi Finnes, Board Liaison

Public Policy Committee
Timothy Tyler, Chair
Sarah Hudson-DiSalle, Vice Chair
Ryan Bookout, Board Liaison
Susannah Koontz, Board Liaison
Susanne Liewer, Board Liaison
Justin Arnall
Mark Hamm
Megan Hartranft
Ali McBride
Taylor Monson
Elizabeth Rogers
Kathryn Schiavo
Rebecca Tombreston

Publications Committee
Ashley Glode, Editor
Megan Bodge, Associate Editor
Christian Thomas, Associate Editor
Heidi Finnes, Board Liaison
Edward Li, Board Liaison
Jessica Auten
Lisa Cordes
Jeff Engle
Karen Fancher
Craig Freyer
Sarah Hayes
Sarah Hoffman
Kasey Jackson
Emily Kathol
Abby Kim
Houry Leblebjian
Renee McAlister
Sarah Newman
Candice Wenzell

Recognition Committee
LeAnne Kennedy, Chair
Jennifer Davis, Vice Chair
Tim Brenner
Amber Clemons
Susan Goodin
R. Donald Harvey
Lisa Holle
Lauren McBride

Research Council
Vicky Brown, Research—Practice
  Outcomes and Professional
  Benchmarking Committee Chair
Patrick Kiel, Research—Basic and
  Translational Sciences Committee
  Chair
Pamala Pawloski, Grant Reviewers
  Committee Vice Chair
Amy Seung, Research—Practice
  Outcomes and Professional
  Benchmarking Committee Vice Chair
Hai Tran, Research—Basic and
  Translational Sciences Committee
  Vice Chair
Meghana Trivedi, Grant Reviewers
  Committee Chair
Sally Barbour, Board Liaison

Research—Basic and Translational
  Sciences Committee
Patrick Kiel, Chair
Hai Tran, Vice Chair
Jolyln Sessions, Board Liaison
Joseph Bubalo
Lisa Davis
Martina Fraga
Jai Patel
Matthew Saylor
Judith Smith

Research—Practice Outcomes
  and Professional Benchmarking
  Committee
Vicky Brown, Chair
Amy Seung, Vice Chair
Sally Barbour, Board Liaison
Robert Ignoffo, Mentor
Maurice Alexander
Paul Cockrum
Vineet Gopinathan
Patricia Grunwald
Stephen Harnicar
Shannon Hough
Benym Muluneh
Ginah Nightingale
Kerry Parsons
Grażyna Riebandt
Angela Urmanski

Standards Committee
Lindsay Stansfield, Chair
Bernadette Heron, Vice Chair
Sol Atienza
Jill Bates
Kourtney LaPlant
Deborah McCue
Man Yee Merl
Julianna Roddy
Amanda Seddon

Tools and Resources Committee
Caren Hughes, Chair
David DeRemer, Vice Chair
Leah Edenfield
Rachel Elsey
Heidi Finnes
Jerline Hsin
Andrea Iannucci
Jared Matya
Rachel McDevitt
Abby Miske
Elizabeth Pritchard
Angela Wood

Entry-Level Competencies in
Hematology/Oncology Pharmacy
Practice for Graduates of the
Doctor of Pharmacy Degree and
Post Graduate Year 1 Pharmacy
Practice Residency Task Force
Gina Nightingale, Chair
Ila Saunders, Vice Chair
Jill Comeau
Karen Fancher
Tim Miller
Jason Yeh

Global Health Task Force
Meagan Barbee, Chair
Benym Muluneh, Chair
Evelyn Handel, Vice Chair
Larry Buie, Board Liaison
Karen Fancher
Christina Mactal Haaf
Julie Kennerly-Shah
Hillary Prescott
Amber Rexwinkle

Journal Task Force
Ashley Glode, Chair
Megan Bodge, Vice Chair
Ryan Bookout, Board Liaison
Robert Mancini
Scott Soefje
Marisela Tan
Christian Thomas

Oral Chemotherapy Patient
Education Handout Task Force
Lisa Holle, Chair
Ashley Glode, Vice Chair
Jason Bergsakken
Sarah Cimino
Kaylee Drenker
Lauren Dubois
Evelyn Handel
Emily Kathol
Julianne Orr
Eve Segal
Sara Smith
Lindsay Stansfield
Audrea Szabatura
Colleen Westendorf-Overley

Oral Chemotherapy Standards
Committee Task Force
Emily Mackler, Chair
Jenna Carmichael
Kate Jeffers
Benym Muluneh
Eve Segal

Quality Oversight Task Force
Emily Mackler, Chair
Amy Seung, Vice Chair
Ryan Bookout, Board Liaison
George Carro
Steve D’Amato
Evelyn Handel
Julianne Orr
Judith Smith

Roles and Responsibilities of
the Pharmacy Technician in
Ambulatory Oncology Pharmacy
Task Force
Danielle Roman
Deborah Sandoval

Scope of Hematology/Oncology
Pharmacy Practice (Part 2) Task
Force
Lisa Holle, Chair
Jill Bates
Sara Fleszar
Julie Kennerly-Shah
Elizabeth Koselke
Michelle Rockey
Eve Segal
Deborah Ward

Time to Talk Immuno-Oncology
Task Force
Heidi Finnes, Chair
Amber Proctor, Vice Chair
Susanne Liewer, Board Liaison
Christopher Campen
Jessica Davis
Sarah Fleszar
Kelly Fritz
Mimi Lo
Kristoffer Martinson
Brenna Rowen
Chrystia Zobniw
HOPA has become the true home for oncology/hematology pharmacy: we have expanded and diversified our membership, increased meeting attendance, provided more and varied educational opportunities, and enhanced the number and value of our collaborations.”

—Ryan Bookout, PharmD BCOP, 2018–2019 HOPA President